Neuromotor Sciences News Today

Genetic testing to determine the best antidepressant for patients with major depression and has the potential to lead to an optimal drug choice on the first try and reduce healthcare costs, new research suggests.

The presence of p-syn on the skin distinguishes people with Parkinson's disease from those with Parkinson's symptoms associated with other neurological disorders.

A novel study has found that the presence of neuronal deposits of the biomarker phosphorylated alpha-synuclein (p-syn) in the brain and the skin of patients with PD distinguishes them from individuals with symptoms of parkinsonism due to the accumulation of another protein, tau.

The diagnosis of Parkinson's disease (PD) is currently based on consensus clinical criteria. A novel study reported in the Journal of Parkinson's Disease has found that the presence of neuronal deposits of the biomarker phosphorylated alpha-synuclein (p-syn) in the brain and the skin of patients with PD distinguishes them from individuals with symptoms of parkinsonism due to the accumulation of another protein, tau.

Researchers of the University of Bologna carried out a study on murine models (mice) demonstrating that pre-natal exposure to nicotine and its by-products produces long-term effects on sleep and stress-response in some areas of the brain.

Pre-natal exposure to nicotine and its by-products produces long-term effects on sleep and stress-response in some areas of the brain.

Study demonstrates contralateral transfer of LUMEVOQ after unilateral injection Results suggest mechanistic explanation for bilateral improvement of visual function among ND4-LHON patients

Clinically meaningful difference between visual outcomes of LUMEVOQ®-treated patients and untreated patients Regulatory News: GenSight Biologics ...

Press release content from Business Wire. The AP news staff was not involved in its creation. GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye May 3, 2021 GMT Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire) Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire) PARIS--(BUSINESS WIRE)--May 3, 2021-- Regulatory News:...

Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the journal of the American Academy of Ophthalmology, Ophthalmology ® gene therapy in ND4 Leber Hereditary Optic Neuropathy (LHON) subjects. The paper*, published in the January issue under the title, �...